Andrew D. Goldberg - 24 Jun 2024 Form 4 Insider Report for Tarsus Pharmaceuticals, Inc. (TARS)

Role
Director
Signature
/s/ Scott Sieckert, Attorney-in-Fact
Issuer symbol
TARS
Transactions as of
24 Jun 2024
Transactions value $
$0
Form type
4
Filing time
25 Jun 2024, 18:26:18 UTC
Previous filing
14 Jun 2024
Next filing
11 Mar 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TARS Common Stock Options Exercise +3.35K +111.67% 6.35K 24 Jun 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TARS Restricted Stock Units Options Exercise $0 -3.35K -100% $0.00* 0 24 Jun 2024 Common Stock 3.35K Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Company's common stock.
F2 Each RSU represents a contingent right to receive one share of the Company's common stock.
F3 RSUs granted on June 22, 2023, in connection with the Reporting Person's service as a non-employee director as of the Company's 2023 annual meeting of stockholders. The RSUs will vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service.